

Special Issue

Omics Technologies and Genomic Studies Unraveling Alzheimer's Disease Heterogeneity

Message from the Guest Editor

Alzheimer's disease (AD) is a heterogeneous and complex phenotype. Both environmental and genetic factors significantly influence AD. Ongoing research aims to elucidate the biological diversity of AD through multi-omics approaches in both peripheral and brain tissues, including single-cell analyses, biomarkers, endophenotypes, imaging, etc. Over 70 genetic loci and various biomarkers have been linked to AD, indicating that multiple pathways may contribute to this disease. Additionally, it is important to note that some individuals exhibit AD pathology without displaying any symptoms. Addressing the heterogeneity of AD is crucial for accurate diagnosis, prevention, treatment, and prediction of disease progression. We invite submissions that explore the heterogeneity of AD, including studies conducted within diverse populations that report novel discoveries or evaluate existing AD markers in new populations. Furthermore, literature reviews and bioinformatics publications that propose innovative methodologies for studying disease heterogeneity are also encouraged.

Guest Editor

Dr. Perry G. Ridge
Department of Biology, Brigham Young University, Provo, UT, USA

Deadline for manuscript submissions

closed (31 July 2025)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/228912

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.